ProCE Banner Activity

CE / CME

Managing Increased Cancer Risk in Transgender Individuals With HIV Infection

Text Module

In this focused module, review expert strategies for optimizing cancer screening, management, and clinical trial enrollment of transgender persons living with HIV at increased risk for certain hematologic and solid cancers.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour, including 0.75 hour of pharmacotherapy credit 

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 07, 2022

Expiration: November 06, 2023

No longer available for credit.

Share

Faculty

Ariela Noy

Ariela Noy, MD

Member and Attending Physician
Lymphoma Service 
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for all healthcare professionals across multiple disciplines and specialties who care for transgender individuals, including medical oncologists, gynecologists, HIV specialists, primary care physicians, pharmacists, nurses, and nurse practitioners.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the potentially disproportionately increased risk of transgender individuals for contracting HIV and the increased risk of developing several types of cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Ariela Noy, MD

Member and Attending Physician
Lymphoma Service 
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Ariela Noy, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Cornerstone, Epizyme, Janssen, Morphosys, TGI Therapeutics.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.

Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, MorphoSys, Pfizer, Regeneron, Sanofi.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-279-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 07, 2022, through November 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this education is to advance knowledge, competence, and performance of healthcare professionals to ensure they are providing inclusive care for all patients, including cancer screening and preventive care for transgender individuals.